vendredi 7 octobre 2016

Onco Actu du 7 octobre 2016

2. Etiologie

Working night shifts unlikely to increase breast cancer risk [Cancer Research UK]

Breast cancer risk 'not increased' by night shifts [BBC News]

3.1.1 Tabac - e-cigs

For less toxic e-cigarettes, skip the strawberry [Reuters]

3.3 Prévention - Vaccins

As Parents Consider the HPV Vaccine, the Message Matters [Cancer Research Catalyst]

4.1 Dép., diag. & prono. - Prostate

No, the PSA test probably didn’t save Ben Stiller’s life [Respectful Insolence]

4.7 Dép., diag. & prono. - Col de l'utérus

Cervical screening every 10 years for healthy women is 'safe' [NHS Choices]

4.9 Dép., diag. & prono. - Sein

Do You Need Extra Screening For Breast Cancer? The Picture Is Blurry [NPR]

5. Traitements

Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer [NCI]

Daratumumab for Myeloma [Now@NEJM]

5.12 Immunothérapies

For cancer patients, newest treatments force the ultimate decision, with no room for error [STAT]

5.2.1 Pharma - Partenariats

CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration [Cancer Research UK]

5.4 Traitements - Economie

How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price [The Street]

5.6 ESMO

Myriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting [Myriad]

ESMO 2016 Press Release: Improving Cancer Screening Participation Should be a Priority [ESMO]

5.6.2 ESMO - Divers

ESMO 2016 Press Release: High response rate in phase I/II paediatric brain cancer trial sets stage for combination therapy with higher response and lower toxicity [ESMO]

5.6.4 ESMO - Poumon

ESMO 2016 Press Release: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer [ESMO]

5.6.5 ESMO - Mélanome & Peau

ESMO 2016 Press Release: Thousands of melanoma patients in Europe have no access to new life saving drugs [ESMO]

Thousands of European melanoma patients lack access to new drugs [Reuters]

5.6.6 ESMO - Sein

Pilot project provides a snapshot of effectiveness of Pfizer’s PARP contender talazoparib [EndPoints]

6. Lutte contre les cancers

MAP conference 2016: proving the potential of personalised medicine [Cancer Research UK]

6.10.1 Politiques (USA)

Exclusive: U.S. lawmakers to investigate funding of WHO cancer agency [Reuters]

6.7.2 Applis

It’s not just apps. Health care innovation requires true communication [STAT]